The findings of this study suggest the potential of AMK as a therapeutic agent for IBS, primarily through the modulation of ion channels, particularly TRPV1, which is involved in reducing the visceral hypersensitivity associated with IBS. The gene discussed is TRPV1; the disease is irritable bowel syndrome.